Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335553 · ClinicalTrials.gov registry record · Phase 1
A Study of Experimental Medication BMS-986235 in Healthy Subjects
A Phase 1 study of Mediators of Inflammation, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
- 2
- Study locations
NCT03335553 is a Phase 1 study of Mediators of Inflammation that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 122 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03335553, a Phase 1 study of Mediators of Inflammation, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a study of experimental medication BMS-986235 in healthy subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BMS-986235
Study Locations (2)
California
- Anaheim Clinical Trials - Anaheim
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2021-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03335553
The ClinicalTrials.gov registry entry for NCT03335553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mediators of Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03335553 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Utah.
Frequently Asked Questions
What is clinical trial NCT03335553 about?
NCT03335553 is a clinical study titled "A Study of Experimental Medication BMS-986235 in Healthy Subjects". This is a study of experimental medication BMS-986235 in healthy subjects.
What is the current status of trial NCT03335553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2017-11-15. Estimated completion is 2021-07-02.
What conditions does trial NCT03335553 study?
This clinical trial studies the following conditions: Mediators of Inflammation.
What interventions are being tested in trial NCT03335553?
The interventions under investigation include: Placebo (OTHER), BMS-986235 (DRUG).
Who is sponsoring clinical trial NCT03335553?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03335553 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.